S&P 500 7,757.17 +0.58%
Nasdaq 26,702.86 +1.05%
S&P/TSX 36,324.99 +0.60%
Apple 343.99 +1.32%
Nvidia 221.97 +2.54%
Microsoft 532.95 +0.20%
Shopify 244.93 +0.38%
Royal Bank 283.62 +1.23%
CAD/USD 0.7119 +0.14%
AFTER HRS · 18:25 ET
Market ClerkRecap
Wed Oct 21 · after hours2 signals today106 insider buys this week · $305.5MCIRO short report next: Oct 31The week ahead

EXEL

EXELIXIS, INC.
NASDAQ · HEALTH CARE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
64.58
+0.19 +0.30%
USD · close Oct 21

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

MKT CAP $16BP/E 20.3DIV YIELD —FCF YIELD 7.33%REV TTM $2.4B +9.2%NET INCOME $860.6M +42.9%NET CASH $281.4M52W 36.08 – 64.58SEC XBRL · TTM TO Invalid Date

Financials

SEC XBRL · 70 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q2 2027 · Jul 3$628.7M+10.6%96.7%$248.4M$212.1M+14.7%0.82$307.7M$6.8M$300.9MAug 5
Q1 2027 · Apr 3$610.8M+10.0%96.7%$251.3M$210.5M+31.9%0.79$251.8M$1.5M$250.3MMay 5
Q4 2026 · Jan 2derived$598.7M+5.6%95.6%$235.2M$244.5M+74.8%0.88$333.5M$1.2M$332.4MFeb 10
Q3 2026 · Oct 3$597.8M+10.8%96.9%$236.5M$193.6M+64.1%0.69$290.3M$1.5M$288.8MNov 4
Q2 2026 · Jul 4$568.3M−10.8%96.6%$213.6M$184.8M−18.3%0.65$49M$2.8M$46.2MAug 5
Q1 2026 · Apr 4$555.4M+30.6%96.5%$186.9M$159.6M+327.7%0.55$211.4M$3M$208.5MMay 5
Q4 2025 · Jan 3derived$566.8M+18.2%96.5%$163.2M$139.9M+63.5%0.48$240.3M$4M$236.3MFeb 10
Q3 2025 · Sep 27$539.5M+14.3%96.8%$136.1M$118M+11232.7%0.40$271.3M$8.2M$263.1MNov 4
Q2 2025 · Jun 28$637.2M—97.2%$275.9M$226.1M—0.77$119.5M$6.6M$113MJul 28
Q1 2025 · Mar 29$425.2M—95.0%$29.5M$37.3M—0.12$68.8M$9.7M$59.1MMay 13
Q4 2024 · Dec 29derived$479.7M—95.5%$81.8M$85.5M—0.27$10.6M$13.1M−$2.6MFeb 10
Q3 2024 · Sep 29$471.9M—96.0%−$17.6M$1M—0.00$117.4M$9.4M$108MOct 29

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2026 · to Jan 2$2.3B96.4%$872.2M$782.6M33.7%2.78$884.3M$8.4M$875.8M$947.5M—
FY2025 · to Jan 3$2.2B96.5%$604.6M$521.3M24.0%1.76$700M$28.4M$671.5M$652M—
FY2024 · to Dec 29$1.8B96.0%$170.9M$207.8M11.4%0.65$333.3M$40.5M$292.9M$550.4M—
FY2023 · to Dec 30$1.6B96.4%$201.5M$182.3M11.3%0.56$362.6M$27.7M$334.9M$0—
FY2022 · to Dec 31$1.4B96.3%$286.7M$231.1M16.1%0.72$400.8M$54.2M$346.6M$0—
FY2021 · to Jan 1$987.5M96.3%$110.1M$111.8M11.3%0.35$209M$30.3M$178.6M——

Every number comes from EXELIXIS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch EXEL. Know when insiders buy.
One email the day a filing lands. Free.